Acute

Report Titled: “Acute Myeloid Leukemia Market – Growth, Trends, and Forecast (2019 – 2024)

The Research Report on “Acute Myeloid Leukemia Market” 2019 report includes every aspect of the Acute Myeloid Leukemia industry along with the progress performance. Acute Myeloid Leukemia Market report presents an analysis of market size, share, and growth, trends, and price structure, statistical and detailed data of the Acute Myeloid Leukemia industry. Additionally, Acute Myeloid Leukemia Market 2019 research report offers key analysis on the industry status of the Acute Myeloid Leukemia producers with market size, growth, share, trends as well as business price structure.

The Acute Myeloid Leukemia Market report is a professional and detailed study on the Acute Myeloid Leukemia business. Acute Myeloid Leukemia market to predict future market directions between the forecast periods from 2019 to 2024 providing you with vital data for your business decisions.

Get a Sample Copy of the Report – https://www.industryresearch.co/enquiry/request-sample/13999534

Scope of the Report:

  • This report estimates the global acute myeloid leukemia market and includes a detailed analysis of cytarabine, anthracycline drugs, and daunomycin.
  • Acute myeloid leukemia is also known as acute myelogenous leukemia, acute myeloblastic leukemia, acute granulocytic leukemia, or acute non-lymphocytic leukemia. In acute myeloid leukemia, there is a rapid production of abnormal white blood cells that get collected in the bone marrow and disturb the production of normal blood cells. White blood cells guard the body against infections caused by bacteria.

    Market Overview:

  • The global acute myeloid leukemia market was valued at USD 701.6 million in 2018, and is estimated to be valued at USD 1,539.99 million in 2024, witnessing a CAGR of 14.0%. The key factors propelling the growth of this market are high Incidence and prevalence of acute myeloid leukemia, advancements in pharmacology and molecular biology to promote drug development, and increasing investments in R&D by the pharmaceutical companies.
  • The American Cancer Society’s estimates for leukemia in the United States, for 2019, indicates that approximately 61,780 new cases of leukemia and 22,840 deaths from leukemia are expected to occur in the country. Among them, the number of new cases of acute myeloid leukemia (AML) will be around 21,450, from which most of the population will be adults. In terms of mortality, the society has estimated that there will be around 10,920 deaths due to AML, in the country. This statistics shows that there is a huge number of people that are prone to suffer from acute myeloid leukemia, which may directly impact the growth of the AML market in the United States.
  • In addition, the global rise in the incidence of AML, along with increased mortality due to the disease, is expected to create a huge demand for AML therapeutics, thus, augmenting the global AML market.

    Acute Myeloid Leukemia Report Also Covers Offer for New Project Includes:

    • Market Entry Strategies
    • Countermeasures of Economic Impact
    • Marketing Channels
    • Feasibility Studies of New Project Investment
    • Research Conclusions of the Acute Myeloid Leukemia Industry

    The report provides key statistics on the market status of the Acute Myeloid Leukemia Market manufacturers and is a valuable source of guidance and direction for companies and individuals interested in the Acute Myeloid Leukemia.

    Enquire Before Purchasing this Report – https://www.industryresearch.co/enquiry/pre-order-enquiry/13999534

    Acute Myeloid Leukemia Market Report Also Covers Marketing Strategy Analysis, Top Manufacturers:

  • Celegene Corporation
  • Novartis AG
  • Genmab AS
  • Eisai Co. Ltd
  • Sanofi
  • Aventis (Genzyme Corporation)
  • Teva Pharmaceutical (Cephalon Inc.)
  • Pfizer Inc.
  • Bristol
  • Myers Squibb Company
  • Sunesis Pharmaceuticals Inc.

    Key Market Trends:

    Cytarabine is Expected to hold its Highest Market Share in the Chemotherapy Segment

    In the chemotherapy segment of the acute myeloid leukemia market, cytarabine is believed to have the largest market size and is expected to witness a CAGR of 14.3% during the forecast period.

    Most of the times, surgery and radiation therapy in cancer patients remove, kill, or damage cancer cells in a certain area, but chemotherapy works throughout the whole body and gives better results. Chemotherapy is necessary to kill the cancer cells that are spread (metastasized) across different parts of the body. On the contrary, surgery and radiation only attack or kill the tumor that is located in a specific part. Since cancer is the disease which, most of the times, spreads across the whole body in a short period of time, oncologists choose to perform chemotherapy for better results.

    Cytarabine is used to treat different forms of leukemia, including acute and chronic myelogenous leukemia (AML and CML), acute lymphocytic leukemia (ALL), and acute promyelocytic leukemia (APL). It is also used to treat Hodgkin’s lymphoma, as well as meningeal leukemia and other types of lymphoma (cancers found in the lining of the brain and spinal cord). Due to its effectiveness in the treatment of acute myeloid leukemia, cytarabine is being widely used during chemotherapy. Organizations that are working for cancer, such as Macmillan Cancer Support, have stated that cytarabine is more effective for acute myeloid leukemia, which is why the drug is used widely; therefore, this sub-segment is expected to have a large market share in the chemotherapy segment.

    North America Dominates the Market and is Expected to do Same in the Forecast Period

    North America currently dominates the market for acute myeloid leukemia and is expected to continue its stronghold for a few more years. The United States holds the largest share of the market. The United States has a unique healthcare system among the developed countries. However, the cost of hospitals is very high in the country; the government or private insurance cover it. Most of the people opt for private insurance as government insurance has its own limitations. The American Cancer Society had estimated around 21,380 new cases of acute myeloid leukemia (AML) and approximately 10,590 deaths from AML in the United States, in 2016.

    According to this society, these statistics involve a large percentage of the adult population. The increasing number of AML patients in the United States require proper medical procedures to increase their life expectancy. The rising prevalence of AML in the country is the prime factor responsible for the growth of the market in the country.

    Purchase this Report (Price 4250 USD for Single User License) – https://www.industryresearch.co/purchase/13999534

    Detailed TOC of Acute Myeloid Leukemia Market Report are:

    1 INTRODUCTION
    1.1 Study Deliverables
    1.2 Study Assumptions
    1.3 Scope of the Study

    2 RESEARCH METHODOLOGY

    3 EXECUTIVE SUMMARY

    4 MARKET DYNAMICS
    4.1 Market Overview
    4.2 Market Drivers
    4.2.1 High Incidence and Prevalence of Acute Myeloid Leukemia
    4.2.2 Advancement in Pharmacology and Molecular Biology to Promote Drug Development
    4.2.3 Increasing Investments in R&D
    4.3 Market Restraints
    4.3.1 Stringent Regulations on Drugs
    4.3.2 Complications Related to Chemotherapy
    4.4 Porter’s Five Forces Analysis
    4.4.1 Threat of New Entrants
    4.4.2 Bargaining Power of Buyers/Consumers
    4.4.3 Bargaining Power of Suppliers
    4.4.4 Threat of Substitute Products
    4.4.5 Intensity of Competitive Rivalry

    5 MARKET SEGMENTATION
    5.1 Chemotherapy
    5.1.1 Cytarabine
    5.1.2 Anthracycline Drugs
    5.1.2.1 Daunomycin
    5.1.2.2 Idarubicin
    5.1.2.3 Mitoxantrone
    5.1.3 Alkylating Agents
    5.1.4 Anti-metabolites
    5.1.5 Tyrosine Kinase Inhibitors
    5.1.5.1 Dasatinib (Sprycel)
    5.1.5.2 Imatinib (Gleevec)
    5.1.6 Hormonal Therapy
    5.1.7 Other Chemotherapies
    5.2 Geography
    5.2.1 North America
    5.2.1.1 United States
    5.2.1.2 Canada
    5.2.1.3 Mexico
    5.2.2 Europe
    5.2.2.1 Germany
    5.2.2.2 United Kingdom
    5.2.2.3 France
    5.2.2.4 Italy
    5.2.2.5 Spain
    5.2.2.6 Rest of Europe
    5.2.3 Asia-Pacific
    5.2.3.1 China
    5.2.3.2 Japan
    5.2.3.3 India
    5.2.3.4 Australia
    5.2.3.5 South Korea
    5.2.3.6 Rest of Asia-Pacific
    5.2.4 Middle East & Africa
    5.2.4.1 GCC
    5.2.4.2 South Africa
    5.2.4.3 Rest of Middle East & Africa
    5.2.5 South America
    5.2.5.1 Brazil
    5.2.5.2 Argentina
    5.2.5.3 Rest of South America

    6 COMPETITIVE LANDSCAPE
    6.1 Company Profiles
    6.1.1 Celegene Corporation
    6.1.2 Novartis AG
    6.1.3 Genmab AS
    6.1.4 Eisai Co. Ltd
    6.1.5 Sanofi-Aventis (Genzyme Corporation)
    6.1.6 Teva Pharmaceutical (Cephalon Inc.)
    6.1.7 Pfizer Inc.
    6.1.8 Bristol-Myers Squibb Company
    6.1.9 Sunesis Pharmaceuticals Inc.

    7 MARKET OPPORTUNITIES AND FUTURE TRENDS

     

    Contact Us:

    Name: Ajay More

    Phone: US +14242530807/ UK +44 20 3239 8187

    Email: [email protected]

    Our Other Reports:

    Bamboo Flooring Market 2019 Global Industry Trends, Size, Segments, Competitors Strategy, Regional Analysis, Review, Key Players Profile, Statistics and Growth to 2024 Analysis

    Biogas Generator Market 2019 by Growth Rate, Key Manufacturers, Market Size, Market Current Status, Share, Latest Opportunities Forecast to 2025

    Global Human Insulin Market Research Report 2019 Focused on Product Scope, Market Overview, and Opportunities Forecast to 2024